One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The Platinum Hall of Fame
doi : 10.1016/j.eururo.2023.12.010
Volume 85, Issue 2, February 2024, Pages e29-e39
Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise
Badar M. Mian
doi : 10.1016/j.eururo.2023.05.039
Volume 85, Issue 2, February 2024, Pages 99-100
Does Urologist-level Utilization of Active Surveillance for Low-risk Prostate Cancer Correspond with Utilization of Active Surveillance for Small Renal Masses?
Michael Wang a,*, Sophie Wittenberg a , Michael L. Cher a , Monica Van Til b , Stephanie Ferrante b , Mahin Mirza b , Anna Johnson b , Alice Semerjian c , Arvin George b , Craig Rogers d , Samantha Wilder d , Richard Sarle e , Khurshid R. Ghani b , Brian Lane f , Kevin B. Ginsburg a , for the Michigan Urological Surgery Improvement Collaborative
doi : 10.1016/j.eururo.2023.07.005
Volume 85, Issue 2, February 2024, Pages 101-104
Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial
Matthias Boschheidgen a , Peter Albers b,c , Heinz-Peter Schlemmer d , Susanne Hellms e , David Bonekamp d , Andreas Sauter f , Boris Hadaschik g , Agne Krilaviciute c , Jan Philipp Radtke b , Petra Seibold c , Jale Lakes b , Christian Arsov b,h , Ju¨rgen E. Gschwend i , Kathleen Herkommer i , Marcus Makowski f , Markus A. Kuczyk j , Frank Wacker e , Nina Harke j , Ju¨rgen Debus k , Stefan A. Ko¨rber k , Axel Benner l , Glen Kristiansen m , Frederik L. Giesel n , Gerald Antoch a,o , Rudolf Kaaks p , Nikolaus Becker c , Lars Schimmo¨ller
doi : 10.1016/j.eururo.2023.09.027
Volume 85, Issue 2, February 2024, Pages 105-111
When Is It Too Early To Start Prostate Cancer Screening? Reflections on the PROBASE Study Using Magnetic Resonance Imaging for Men Aged 45 Yr with Elevated Prostate-specific Antigen
Caroline M. Moore a,b,*, Peter Albertsen
doi : 10.1016/j.eururo.2023.10.015
Volume 85, Issue 2, February 2024, Pages 112-113
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma
Thomas Powles a,*,y, Zoe June Assaf b,y, Viraj Degaonkar b , Petros Grivas c , Maha Hussain d , Stephane Oudard e , Ju¨rgen E. Gschwend f , Peter Albers g , Daniel Castellano h , Hiroyuki Nishiyama i , Siamak Daneshmand j , Shruti Sharma k , Himanshu Sethi k , Alexey Aleshin k , Yi Shi b , Nicole Davarpanah b , Corey Carter b , Joaquim Bellmunt l,à , Sanjeev Mariathasan
doi : 10.1016/j.eururo.2023.06.007
Volume 85, Issue 2, February 2024, Pages 114-122
Towards Tailored Adjuvant Therapy in Bladder Urothelial Carcinoma: How Should We Fit Each Size?
Natacha Naoun a,b , Yohann Loriot
doi : 10.1016/j.eururo.2023.09.020
Volume 85, Issue 2, February 2024, Pages 123-124
The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies
Marcin Miszczyk a,b,y, Pawel Rajwa c,d,y, Takafumi Yanagisawa c,e , Zuzanna Nowicka f , Sung Ryul Shim g , Ekaterina Laukhtina c , Tatsushi Kawada c,h , Markus von Deimling c,i , Benjamin Pradere c,j , Juan Go´mez Rivas k , Giorgio Gandaglia l , Roderick C.N. van den Bergh m , Gregor Goldner a , Stephane Supiot n , Thomas Zilli o , Quoc-Dien Trinh p , Paul L. Nguyen q , Alberto Briganti l , Piet Ost r , Guillaume Ploussard j , Shahrokh F. Shariat
doi : 10.1016/j.eururo.2023.10.012
Volume 85, Issue 2, February 2024, Pages 125-138
Robot-assisted Periprostatic Artificial Urinary Sphincter Implantation in Men with Neurogenic Stress Urinary Incontinence: Description of the Surgical Technique and Comparison of Long-term Functional Outcomes with the Open Approach
Edward Lambert a,b,*, Emmanuel Chartier-Kastler a,c , Christophe Vaessen a , Aure´lien Beaugerie a,c , Juliette Cotte a,c , Morgan Roupret a,c , Pierre Mozer a,c , Je´roˆme Parra a , Thomas Seisen a,c , Louis Lenfant a,c , Also on behalf of the Junior ERUS / EAU-YAU Working Group on Robot-Assisted Surgery
doi : 10.1016/j.eururo.2023.09.025
Volume 85, Issue 2, February 2024, Pages 139-145
Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology
Michael Eppler a,b , Conner Ganjavi a,b , Lorenzo Storino Ramacciotti a,b , Pietro Piazza c , Severin Rodler d , Enrico Checcucci e , Juan Gomez Rivas f , Karl F. Kowalewski g , Ines Rivero Belencho´n h , Stefano Puliatti i , Mark Taratkin j , Alessandro Veccia k , Lo?¨c Baekelandt l , Jeremy Y.-C. Teoh m , Bhaskar K. Somani n , Marcelo Wroclawski o,p,q , Andre Abreu a,b , Francesco Porpiglia e , Inderbir S. Gill a,b , Declan G. Murphy r , David Canes s , Giovanni E. Cacciamani
doi : 10.1016/j.eururo.2023.10.014
Volume 85, Issue 2, February 2024, Pages 146-153
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance
Srikala S. Sridhar a,*, Thomas Powles b , Miguel A´. Climent Dura´n c , Se Hoon Park d , Francesco Massari e,f , Antoine Thiery-Vuillemin g , Begon?a P. Valderrama h , Anders Ulle´n i,j , Norihiko Tsuchiya k , Jeanny B. Aragon-Ching l , Shilpa Gupta m , Daniel P. Petrylak n , Joaquim Bellmunt o , Jing Wang p , Robert J. Laliberte p , Alessandra di Pietro q , Nuno Costa r , Petros Grivas s , Cora N. Sternberg t , Yohann Loriot
doi : 10.1016/j.eururo.2023.08.001
Volume 85, Issue 2, February 2024, Pages 154-163
European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy—A Multicenter Study
Felix Preisser a,b,y, Raisa S. Abrams-Pompe a,c,y, Piter Jan Stelwagen d , Dirk Bo¨hmer e , Fabio Zattoni f , Alessandro Magli g,h , Juan Go´mez Rivas i , Roser Vives Dilme i , Matteo Sepulcri j , Aritz Eguibar k , Isabel Heidegger l , Christoph Arnold m , Christian D. Fankhauser n,o , Felix K.-H. Chun b , Henk van der Poel d , Giorgio Gandaglia p , Thomas Wiegel q , Roderick C.N. van den Bergh r , Derya Tilki a,c,s,*, on behalf of the EAU-YAU Prostate Cancer Working Group
doi : 10.1016/j.eururo.2023.05.038
Volume 85, Issue 2, February 2024, Pages 164-170
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel
Primo N. Lara Jr a,*, Edward Mayerson b , Erik Gertz c , Catherine Tangen b , Amir Goldkorn d , Marta van Loan c , Maha Hussain e , Shilpa Gupta f , Jingsong Zhang g , Mamta Parikh a , Przemyslaw Twardowski h , David I. Quinn d , Michael LeBlanc b , Nicholas J. Vogelzang i , Ian Thompson j , Neeraj Agarwal
doi : 10.1016/j.eururo.2023.03.036
Volume 85, Issue 2, February 2024, Pages 171-176
Re: Deep Learning Imaging Features Derived from Kidney Ultrasounds Predict Chronic Kidney Disease Progression in Children with Posterior Urethral Valves
Lisette A. ’t Hoen
doi : 10.1016/j.eururo.2023.08.021
Volume 85, Issue 2, February 2024, Pages 177-178
Re: Rakesh Heer, Rebecca Lewis, Thenmalar Vadiveloo, et al. A Randomized Trial of PHOTOdynamic Surgery in Non–muscle-invasive Bladder Cancer. NEJM Evid 2022;1:EVIDoa2200092
Jonathan Sussman a Badrinath Konety a,b Hamed Ahmadi
doi : 10.1016/j.eururo.2023.07.017
Volume 85, Issue 2, February 2024, Pages 178-179
Re: Patient-reported Outcomes 12 Years after Localized Prostate Cancer Treatment
Abhishek D. Sharma a,b,* Daniel W. Good a S. Alan McNeill
doi : 10.1016/j.eururo.2023.09.026
Volume 85, Issue 2, February 2024, Page 179
Re: Low Cancer Yield in PI-RADS 3 Upgraded to 4 by Dynamic Contrast-enhanced MRI: Is It Time To Reconsider Scoring Categorization?
Sriram Deivasigamani a Srinath Kotamarti a Rajan T. Gupta a,b Thomas J. Polascik
doi : 10.1016/j.eururo.2023.08.023
Volume 85, Issue 2, February 2024, Pages 180-181
Re: Cardiovascular Safety of Testosterone-Replacement Therapy
Sirpi Nackeeran a Ranjith Ramasamy
doi : 10.1016/j.eururo.2023.09.014
Volume 85, Issue 2, February 2024, Page 181
Re: Cardiovascular Safety of Testosterone-Replacement Therapy
Fabio Campodonico * Marco Ennas
doi : 10.1016/j.eururo.2023.09.029
Volume 85, Issue 2, February 2024, Page 182
Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023; 388:1547–58
Bernardo Rocco Maria Chiara Sighinolfi
doi : 10.1016/j.eururo.2023.06.035
Volume 85, Issue 2, February 2024, Page e40
Reply to Bernardo Rocco and Maria Chiara Sighinolfi’s Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547–58
Freddie C. Hamdy a,* Jenny L. Donovan
doi : 10.1016/j.eururo.2023.08.014
Volume 85, Issue 2, February 2024, Pages e41-e42
Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561–70
André Pontes-Silva
doi : 10.1016/j.eururo.2023.07.024
Volume 85, Issue 2, February 2024, Pages e43-e44
Reply to André Pontes-Silva’s Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561–70
Gabriela Ilie a,b,c,* Robert David Harold Rutledge
doi : 10.1016/j.eururo.2023.08.027
Volume 85, Issue 2, February 2024, Pages e45-e46
Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561–70
Matthias May a,* Ingmar Wolff b Sabine D. Brookman-May c
doi : 10.1016/j.eururo.2023.07.025
Volume 85, Issue 2, February 2024, Pages e47-e48
Reply to Matthias May, Ingmar Wolff, and Sabine D. Brookman-May’s Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561–70
Gabriela Ilie a,b,c,* Robert David Harold Rutledge
doi : 10.1016/j.eururo.2023.08.028
Volume 85, Issue 2, February 2024, Pages e49-e50
Reply to Jared P. Schober, Robert Wang, and Alexander Kutikov’s Letter to the Editor re: Giuseppe Basile, Giuseppe Fallara, Paolo Verri, et al. The Role of 99mTc-Sestamibi Single-photon Emission Computed Tomography/Computed Tomography in the Diagnostic Pathway for Renal Masses: A Systematic Review and Meta-analysis. Eur Urol. 2023;85:63–71
Giuseppe Basile a,b,* Giuseppe Fallara c Arturo Chiti d Alessandro Larcher a Alberto Breda b Umberto Capitanio
doi : 10.1016/j.eururo.2023.11.003
Volume 85, Issue 2, February 2024, Pages e51-e52
Re: Giuseppe Basile, Giuseppe Fallara, Paolo Verri, et al. The Role of 99mTc-Sestamibi Single-photon Emission Computed Tomography/Computed Tomography in the Diagnostic Pathway for Renal Masses: A Systematic Review and Meta-analysis. Eur Urol. 2023;85:63–71
Jared P. Schober a,* Robert Wang b Alexander Kutikov
doi : 10.1016/j.eururo.2023.10.022
Volume 85, Issue 2, February 2024, Page e53
Reply to Greg Shaw, John D. Kelly, and Monique J. Roobol’s Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547–58
Freddie C. Hamdy a,* Jenny L. Donovan
doi : 10.1016/j.eururo.2023.10.018
Volume 85, Issue 2, February 2024, Pages e54-e55
Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547–58
Greg Shaw a,b,* John D. Kelly a,b Monique J. Roobol
doi : 10.1016/j.eururo.2023.08.035
Volume 85, Issue 2, February 2024, Pages e56-e57
Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study� [Eur Urol 84(5) (2023) 449–454]
Elizabeth R. Plimack a,*, Thomas Powles b,c , Viktor Stus d , Rustem Gafanov e , Dmitry Nosov f , Tom Waddell g , Boris Alekseev h , Fre´de´ric Pouliot i , Bohuslav Melichar j , Denis Soulie`res k , Delphine Borchiellini l , Raymond S. McDermott m , Ihor Vynnychenko n , Yen-Hwa Chang o , Satoshi Tamada p , Michael B. Atkins q , Chenxiang Li r , Rodolfo Perini r , L. Rhoda Molife s , Jens Bedke t , Brian I. Rini
doi : 10.1016/j.eururo.2023.11.016
Volume 85, Issue 2, February 2024, Pages e58-e59
Corrigendum to “Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis� [Eur. Urol. 84(1) (2023) 36–48]
Kit Mun Chow a , Wei Zheng So a , Han Jie Lee b , Alvin Lee b , Dominic Wei Ting Yap a , Yemisi Takwoingi c,d , Kae Jack Tay b , Jeffrey Tuan e , Sue Ping Thang f , Winnie Lam f , John Yuen b , Nathan Lawrentschuk g,h , Michael S. Hofman i , Declan G. Murphy j,k , Kenneth Chen
doi : 10.1016/j.eururo.2023.10.016
Volume 85, Issue 2, February 2024, Pages e60-e61
Congress Calendar
doi : 10.1016/j.eururo.2023.12.011
Volume 85, Issue 2, February 2024, Pages e62-e63
